Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Patrys Limited
  6. News
  7. Press Releases
    PAB   AU000000PAB9

PATRYS LIMITED

(PAB)
Delayed Australian Stock Exchange  -  02:10 2022-08-10 am EDT
0.0260 AUD   +8.33%
04:10aPatrys Validates Efficacy of Brain Cancer Drug in Preclinical Animal Study
MT
08/07Patrys Chair to Retire End-August
MT
07/27PATRYS : Appendix 4C - Quarterly - 30 June 2022
PU
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société PATRYS LIMITED
07/27PATRYS : Appendix 4C - Quarterly - 30 June 2022
PU
04/27PATRYS : Appendix 4C - Quarterly - 31 March 2022
PU
04/14PATRYS : Application for quotation of securities - PAB
PU
03/23NEW RESEARCH : Scientists determine structure of a DNA damage ‘First Responder' prot..
PU
02/24PATRYS : Appendix 4D - Half Year Accounts - 31 December 2021
PU
02/07PATRYS : Application for quotation of securities - PAB
PU
02/07PATRYS : ADC Deals Making Headlines
PU
01/30PATRYS : Appendix 4C - Quarterly - 31 December 2021
PU
2021PATRYS : Ceasing to be a substantial holder from MQG
PU
2021PATRYS : Application for quotation of securities - PAB
PU
2021PATRYS : Change of Director's Interest Notices x2
PU
2021PATRYS : Application for quotation of securities - PAB
PU
2021PATRYS : Notification regarding unquoted securities - PAB
PU
2021PATRYS : Notification regarding unquoted securities - PAB
PU
2021Becoming a substantial holder from MQG
PU
2021Rights Issue Offer Document
PU
2021PATRYS LIMITED : Announces Publication of PAT-DX1 Preclinical Data in JCI - Insight
BU
2020PATRYS : Adds Full Human Antibody to Deoxymab Portfolio
PU
2020PATRYS : Adds Full Human Antibody to Deoxymab Portfolio
PU
2020PATRYS : Entitlement Offer Results and Shortfall Notification
PU
2020PATRYS : New Appointment to Scientific Advisory Board
PU
2019PATRYS : Annual Report 2019
PU
2019PATRYS : Presented at Leading Brain Metastases Conference
PU
2019PATRYS : Updated Investor Presentation and Attendance at Bioshares
PU
2019PATRYS : PAT-DX1 Significantly Improves Survival in Aggressive GBM
PU
2019PATRYS : Europe Grants Patent for Deoxymab 3E10
PU
2019PATRYS : Presentation at AACR Conference
PU
2019PATRYS : Presenting at Biotech Showcase
PU
2019PATRYS : Receives R&D Tax Incentive Refund
PU
2018PATRYS : PAT-DX1 Suppresses Breast Cancer Brain Metastases
PU
2018PATRYS : Notice of Annual General Meeting/ Proxy Form
PU
2018PATRYS : and Yale Awarded Grant
PU
2018PATRYS : and WEHI Awarded Grant
PU
2018PATRYS : China and Japan Both Grant Patents for Deoxymab 3E10
PU
2018PATRYS : PAT-DX1 Targets and Kills Brain Cancer Stem Cells
PU
2018PATRYS : Increases Capital Raising to $4.6 Million
PU
2018PATRYS : Announcement of $3.5 Million Share Placement
PU
2018PATRYS : Presents at AACR Conference
PU
2018PATRYS : Publication and Patent Filing for Humanized Version of Deoxymab 3E10
PU
2018PATRYS : PAT-DX1-NP Localizes to Lymph Node Metastases
PU
2017PATRYS : PAT-DX1 Synergistic with PARP Inhibitor
PU
2017PATRYS : PAT-DX1 Active in Pre-clinical Cancer Models
PU
2017PATRYS : rsquo; Deoxymab 3E10 Patent Granted in the U.S.
PU
2017PATRYS : 8 June 2017 – Investor Update
PU
2017PATRYS : 1 May 2017 – Finance Update
PU
2017PATRYS : 19 April 2017 – Deoxymab 3E10 Lead Candidate Confirmed
PU
2016PATRYS : 13 December 2016 – Appointments ot New Scientific Advisory Board
PU
2016PATRYS : 26 September 2016 – Business Review June 2016
PU
2016PATRYS : 30 August 2016 - Appendix 4G & Corporate Governance Statement
PU
2016PATRYS : 30 August 2016 - Appendix 4E & 2016 Annual Report
PU
2016PATRYS : 29 March 2016 - Patrys Acquires License to Novel Nucleus-Pentrating Antibody Asse..
PU
2015PATRYS : 11 November 2015 - Results of Meeting
PU
2015PATRYS : 11 November 2015 - AGM Presentation
PU
2015PATRYS : 27 October 2015 - Appendix 4C - Quarterly 30 September 2015
PU
2015PATRYS : 8 October 2015 - Corporate Governance Statement
PU
2015PATRYS : 30 September 2015 - Corporate Restructure & Change in Company Secretary
PU
2015PATRYS : 29 September 2015 - Market Update
PU
2015PATRYS : 11 September 2015 - Change of Registered Office
PU
2015PATRYS : 14 July 2015 - Appendix 4C -Quarterly 30 June 2015
PU
2015PATRYS : 25 June 2015 - Patrys to License Chinese Rights for PAT-SC1
PU
2015PATRYS : 11 June 2015 - Further Manufacturing Update
PU
2015PATRYS : 1 May 2015 - Announcement of Buy-back - Appendix 3C
PU
2015PATRYS : 19 May 2015 - Final Share Buy-back Notice - Appendix 3F
PU
2015PATRYS : 19 May 2015 - Daily Share Buy-back Notice - Appendix 3E
PU
2015PATRYS : 2 May 2015 - Announcement of Buy-back - Appendix 3C
PU
2015PATRYS : 20 April 2015 - Appendix 4C -Quarterly 31 March 2015
PU
2015PATRYS : 8 April 2015 - Patrys Appoints Dr. James Campbell as CEO
PU
2015PATRYS : 18 February 2015 - Patrys Granted European Patent for PAT-SM6
PU
2014PATRYS : 12 November 2014 - Initial Director's Interest Notice - J Campbell
PU
2014PATRYS : 12 November 2014 - Dr. James Campbell Joins the Patrys Board
PU
2014PATRYS : 12 November 2014 - AGM 2014 Results of Meeting
PU
2014PATRYS : 12 November 2014 - AGM Presentation 2014
PU
2014PATRYS : 29 October 2014 - Update on CEO Position
PU
2014PATRYS : 17 October 2014 - Appendix 4C- Quarterly Cash Flow-Sept 2014
PU
2014PATRYS : 30 September 2014 - Patrys Granted Australian Patent for PAT-LM1
PU
1  2Next
Upcoming event on PATRYS LIMITED
08/25/22FY 2022 Earnings Release (Projected)
Upcoming sector events
10/26/22IQVIA HOLDINGS INC. : Q3 2022 Earnings Release (Projected)
10/27/22ALNYLAM PHARMACEUTICALS, INC. : Q3 2022 Earnings Release (Projected)
10/27/22SEAGEN INC. : Q3 2022 Earnings Release (Projected)
11/03/22MODERNA, INC. : Q3 2022 Earnings Release (Projected)
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Other Biotechnology & Medical Research